- Home
- BGMS vs CDIO Comparison
BGMS vs CDIO Comparison
Compare BGMS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | CDIO |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | 17 |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 6.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BGMS | CDIO |
|---|---|---|
| Price | $1.03 | $1.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.4K | ★ 296.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $137.21 | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.18 |
| 52 Week High | $6.70 | $7.91 |
Technical Indicators
Market Signals| Indicator | BGMS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 39.47 |
| Support Level | $0.74 | $1.64 |
| Resistance Level | $1.13 | $2.03 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 49.84 | 31.75 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.